We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Taken After Miscarriage Can Predict Future Risk of Pregnancy Loss

By LabMedica International staff writers
Posted on 18 May 2023

Approximately 10% of women experience pregnancy loss, a percentage that is higher in regions where pregnancies frequently occur later in a woman's reproductive years. More...

Various factors contribute to pregnancy loss, including hormonal imbalances, endocrine disorders, clotting issues, or lifestyle-related factors. Despite the fact that one in four pregnancies results in a miscarriage, little has been done to investigate the underlying causes, with the primary focus being on the process of uterus evacuation post-miscarriage. Now, a new study has found that a post-miscarriage blood test as early as the fifth week of pregnancy could shed light on the cause and, in some instances, guide preventative treatment strategies. These findings could potentially help prevent 5% of the annual 30 million miscarriages worldwide.

In the study, a team of researchers at Hvidovre Hospital (Hvidovre, Denmark) demonstrated that a blood sample taken from the mother shortly after a miscarriage that occurred as early as the fifth week of pregnancy can identify whether there was a chromosomal abnormality in the fetus. Such tests are typically only administered after a woman has experienced multiple miscarriages and if they occurred past the tenth week of pregnancy.

This blood test can be immediately dispatched to the hospital laboratory. Here, the fetal DNA is isolated, sequenced, and analyzed for chromosomal abnormalities, which are present in approximately 50 to 60% of miscarriages. This analysis allows doctors to identify the severity of these abnormalities and estimate the risk of future miscarriages. If no abnormalities are detected, doctors can then initiate an in-depth investigation for other causes. If a cause is identified, medical professionals can assess the risks and formulate an appropriate treatment plan.

Related Links:
Hvidovre Hospital


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.